Contraline Stock
Contraline is developing the first long-lasting, reversible contraceptive for men
Sign up today and learn more about Contraline Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Contraline Stock
Contraline is a biotechnology company developing a long-lasting, non-hormonal, and reversible male contraceptive.
Funding History
| July 2014 | $0 |
|---|---|
| June 2016 | $680K |
| March 2017 | $2.3M |
| July 2018 | $0 |
| September 2018 | $0 |
Management
COO
Nicole E. Hastings
Co-Founder & CEO
Kevin Eisenfrats
Press
Forbes - Nov, 14 2017
The 2018 30 Under 30 In HealthcareTechCrunch - Apr, 5 2017
Meet the company that’s looking to make non-surgical male birth control a realityEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
